Share issue
2022
Oncopeptides has carried out a directed share issue of approximately SEK 435.6 million (approximately USD 41.1 million)
July 14, 2022 – Regulatory press release
The Board of Directors of Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) has resolved to issue 15,061,443 new shares (the “New Shares”) in a directed share issue to international and Swedish institutional investors based on the authorization granted by the Annual General Meeting on 28 June 2022 (the “Directed Share Issue”). The price for the New Shares is SEK 28.92 per new share, corresponding to the closing price on the day of this announcement of the Oncopeptides share, as traded on Nasdaq Stockholm. A number of international and Swedish investors participated in the Directed Share Issue, including new investors such as Redmile Group, HealthCap VIII and Adrigo Asset Management, as well as the existing shareholders HealthCap VI, Industrifonden and Swedbank Robur Fonder, with demand for the New Shares exceeding the size of the Directed Share Issue. Through the Directed Share Issue, Oncopeptides will receive proceeds amounting to approximately SEK 435.6 million (approximately USD 41.1 million) before transaction costs.